PTC Therapeutics, Inc. (PTCT) — Stock Score Summary

PTC Therapeutics, Inc. (PTCT) has a MoatMap StockRank of 72/100 based on Quality (42/100), Value (52/100), and Momentum (62/100) factor scores. The current signal is BUY. PTC Therapeutics is a clinical-stage biotech with binary regulatory risks and low quality metrics, failing our requirement for predictable, high-ROIC compounders.

PTC Therapeutics, Inc. is a U.S. biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for patients with rare diseases. The company specializes in RNA-focused science and has a portfolio of approved drugs and a robust pipeline targeting genetic disorders such as Duchenne muscular dystrophy and AADC deficiency. Its pioneering work in rare disease treatment and global commercial infrastructure provide a strong position in a high-need therapeutic area.

Key Financial Metrics

Price$73.68
Market Cap$5.9B
P/E (Forward)25.38
Price/Book-28.03
Return on Invested Capital44.0%
Gross Margin37.0%
Operating Margin16.5%
Revenue Growth-76.8%
Free Cash Flow$-418M

PTC Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is PTC Therapeutics, Inc.’s (PTCT) StockRank?
MoatMap’s StockRank for PTC Therapeutics, Inc. (PTCT) is 72/100, with a Buy signal. It is a composite of Quality (42), Value (52), and Momentum (62) factor ranks across MoatMap’s 19,000+ stock universe.
Does PTC Therapeutics, Inc. have an economic moat?
PTC Therapeutics, Inc. (PTCT) has a Quality factor score of 42/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is PTC Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for PTC Therapeutics, Inc. (PTCT) is Buy, based on a StockRank of 72/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is PTC Therapeutics, Inc. in?
PTC Therapeutics, Inc. (PTCT) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksPTCT deep dive reportAI ChampionsHow we score stocksSense-check another stock